Stocktoria
Certara, Inc. CERT
Certara, Inc. (CERT) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $418.8M at a -0.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.104 |
| Retained earnings / assets | -0.083 |
| EBIT / assets | 0.014 |
| Equity / liabilities | 2.152 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CERT | Certara, Inc. | 5/9 | 2.76 | — | +8.7% |
| AVPT | AvePoint, Inc. | 5/9 | 2.72 | 66.3 | +26.9% |
| GDYN | GRID DYNAMICS HOLDINGS, INC. | 6/9 | 12.15 | 47.3 | +17.5% |
| ALKT | ALKAMI TECHNOLOGY, INC. | 3/9 | -0.9 | — | +32.9% |
| XPER | Xperi Inc. | 2/9 | -1.39 | — | -9.2% |
| DDD | 3D SYSTEMS CORP | 4/9 | -5.82 | 16.6 | -12.1% |
| SPT | Sprout Social, Inc. | 4/9 | -2.61 | — | +12.7% |
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
FAQ
Is CERT financially healthy?
Certara, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CERT pay a dividend?
No, Certara, Inc. does not currently pay a dividend.
How profitable is CERT?
In FY2025, Certara, Inc. had a net margin of -0.4% and a return on equity of -0.2%.
What is the analyst price target for CERT?
The average Wall-Street price target for Certara, Inc. is $7.48, about 6.6% below the recent price, from 10 analysts (consensus: buy).
Is CERT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Certara, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.